Arcellx, Inc.

The US Food and Drug Administration’s decision to remove Risk Evaluation and Mitigation Strategies (REMS) requirements for CAR-T cell therapies and streamline patient monitoring will likely expand the

Johnson & Johnson has sought to carve out a leading position in the treatment of multiple myeloma, and presentations at the American Society of Clinical Oncology and European Hematology Associatio

News that oncologist Vinay Prasad will be the new head of the US Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) division sent biopharma shares tumbling on 6 May, as

While Gilead Sciences has seen softening of sales for its approved oncology products, the company is nevertheless showing momentum in its oncology pipeline, particularly for the CAR-T cell therapy ani